Cargando…

OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer

Paclitaxel is a first-line chemotherapeutic for patients with breast cancer, particularly triple-negative breast cancer (TNBC). Molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed since paclitaxel resistance is still a clinical issue in treating TNBC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chiu, Hui-Wen, Lin, Hui-Yu, Tseng, Ing-Jy, Lin, Yuan-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787489/ https://www.ncbi.nlm.nih.gov/pubmed/29416635 http://dx.doi.org/10.18632/oncotarget.23074

Ejemplares similares

High‐level expression of ARID1A predicts a favourable outcome in triple‐negative breast cancer patients receiving paclitaxel‐based chemotherapy
por: Lin, Yuan‐Feng, et al.
Publicado: (2018)

FBXL7 Upregulation Predicts a Poor Prognosis and Associates with a Possible Mechanism for Paclitaxel Resistance in Ovarian Cancer
por: Chiu, Hui-Wen, et al.
Publicado: (2018)

Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma
por: Lin, Dan-dan, et al.
Publicado: (2019)

LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability
por: Li, Peng-Ping, et al.
Publicado: (2021)

Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7
por: Zhang, Zhengkui, et al.
Publicado: (2017)

Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer
por: Kong, W, et al.
Publicado: (2013)

miR-520h Stimulates Drug Resistance to Paclitaxel by Targeting the OTUD3-PTEN Axis in Breast Cancer
por: Geng, Wenwen, et al.
Publicado: (2020)

OTUD7B stabilizes estrogen receptor α and promotes breast cancer cell proliferation
por: Tang, Jianing, et al.
Publicado: (2021)

AtomNet-Aided OTUD7B Inhibitor Discovery and Validation
por: Chen, Jianfeng, et al.
Publicado: (2023)

Otud7b facilitates T cell activation and inflammatory responses by regulating Zap70 ubiquitination
por: Hu, Hongbo, et al.
Publicado: (2016)

MEGF11 is related to tumour recurrence in triple negative breast cancer via chemokine upregulation
por: Chiu, Jen-Hwey, et al.
Publicado: (2020)

Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer
por: Sun, Shanshan, et al.
Publicado: (2021)

Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells
por: Sezer, Gülay, et al.
Publicado: (2022)

A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
por: Liu, Yuetong, et al.
Publicado: (2023)

OTUD7B Deubiquitinates LSD1 to Govern Its Binding Partner Specificity, Homeostasis, and Breast Cancer Metastasis
por: Gong, Zhicheng, et al.
Publicado: (2021)

Upregulation of glycolytic enzyme PFKFB3 by deubiquitinase OTUD4 promotes cardiac fibrosis post myocardial infarction
por: Wang, Feizuo, et al.
Publicado: (2023)

TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis
por: Hu, Jianyang, et al.
Publicado: (2021)

Deubiquitinase OTUD7B is a potential prognostic biomarker in diffuse large B-cell lymphoma
por: Qiu, Shi, et al.
Publicado: (2022)

Upregulation of the ferroptosis-related STEAP3 gene is a specific predictor of poor triple-negative breast cancer patient outcomes
por: Yuan, Lifang, et al.
Publicado: (2023)

GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer
por: Cheng, Shun-Wen, et al.
Publicado: (2021)

Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer
por: Qi, Yanfeng, et al.
Publicado: (2012)

OTUD7B Activates Wnt Signaling Pathway through the Interaction with LEF1
por: Lee, Yuri, et al.
Publicado: (2023)

The Regulation and Double-Edged Roles of the Deubiquitinase OTUD5
por: Fu, Lin, et al.
Publicado: (2023)

B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer
por: Wang, Ling, et al.
Publicado: (2018)

Upregulated expression of AT-rich interactive domain-containing protein 1B predicts poor prognosis in patients with triple-negative breast cancer
por: Cui, Yan, et al.
Publicado: (2019)

Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression
por: Huang, Tzu-Ting, et al.
Publicado: (2020)

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
por: Blanchard, Zannel, et al.
Publicado: (2015)

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
por: Arpino, Grazia, et al.
Publicado: (2015)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023)

Molecular characteristics of recurrent triple-negative breast cancer
por: TSAI, CHUNG-HSIN, et al.
Publicado: (2015)

HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel
por: Lyu, Hui, et al.
Publicado: (2023)

EGFR expression is associated with cytoplasmic staining of CXCR4 and predicts poor prognosis in triple-negative breast carcinomas
por: Li, Rong-Hui, et al.
Publicado: (2017)

Otud7b controls noncanonical NF-κB activation via deubiquitination of TRAF3
por: Hu, Hongbo, et al.
Publicado: (2013)

PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer
por: Song, Wei, et al.
Publicado: (2017)

Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment
por: Chen, Tianyu, et al.
Publicado: (2022)

Investigating the Heterogeneity of Immune Cells in Triple-Negative Breast Cancer at the Single-Cell Level before and after Paclitaxel Chemotherapy
por: Zhao, Heng, et al.
Publicado: (2023)

Corrigendum: PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer
por: Song, Wei, et al.
Publicado: (2017)

Cezanne (OTUD7B) regulates HIF-1α homeostasis in a proteasome-independent manner
por: Bremm, Anja, et al.
Publicado: (2014)

SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer
por: Liu, Xi-Yu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a1k11kmotduifriiortai4um9d